By Austin Stevenson, Chief Revenue Officer
As the U.S. cannabis market continues its rapid evolution, operators across the supply chain are preparing for a decisive 2026. Emerging adult-use markets, tightening state testing regulations, and increasingly discerning consumers aren’t challenges to react to, they’re pressure points exposing ways traditional operating models are already failing.
Most cultivators and processors believe they’re prepared. In reality, the market is shifting faster than many current systems can adapt. Agility, compliance, and scientific precision, once considered optional upgrades, are now baseline requirements. For too long, testing has been seen as a cost center. In 2026, it will become a brand differentiator.
As a leader with experience across all sectors of the cannabis supply chain, I’ve seen firsthand how changing market dynamics can make or break a brand. ACT LAB supports operators navigating this complexity with advanced analytics, multi-state regulatory expertise, and science-backed product development guidance. Here’s what to expect in 2026, and how you can take action to future-proof your business while your competitors are still reacting.
A Changing Regulatory Landscape: What Operators Should Expect
New Adult-Use Markets Will Shift Regional Dynamics
States like Pennsylvania and Florida may see movement toward adult-use cannabis programs, pending ongoing legislative and ballot initiatives, which could reshape supply and demand across surrounding regions. If adult-use markets open up in these states, cultivators can anticipate:
- Increased competition and cross-border brand expansion
- Higher consumer expectations around product safety and consistency
- Faster regulatory shifts as markets scale
Operators planning to launch or scale in these markets can’t afford to treat microbial, solvent, and potency compliance as a late-stage checklist. Early preparation is the only way to avoid costly delays and position products to win on day one.
Stricter Testing Standards and Regulatory Protocols Emerging Across Key States
States with established adult-use programs are tightening rules, and streamlining processes, to align with consumer safety expectations. These changes are a clear signal of where the industry is headed, and underscores how evolving policy will shape market dynamics and testing demand across 2026.
- New York: The state’s track-and-trace system is transitioning to METRC, requiring all licensed operators to be credentialed and reporting inventory by key deadlines. The Office of Cannabis Management (OCM) requires credentialing to be complete by Dec 17, 2025 and inventory must be fully entered by Jan 12, 2026, marking a major compliance shift for cannabis testing workflows in the state.
- Michigan: Environmental monitoring mandates, especially around air, water, and surface contamination, are becoming increasingly likely as regulators prioritize facility hygiene and microbial safety.
- Ohio: The state is refining its cannabis and hemp regulatory framework through legislative efforts like Senate Bill 56. The bill is aimed at overhauling the state’s adult-use cannabis program by tightening THC limits on extracts and concentrates, restricting intoxicating hemp product sales to licensed dispensaries, and enhancing testing and compliance requirements.
As adult-use markets mature, lawmakers and regulators aren’t just tightening rules; they’re redefining the standards for contaminant testing, transparency, and product consistency. Operators who anticipate and align with this shift now will control the competitive narrative.
Federal Policy Signals: Rescheduling Cannabis and the Economics of 280E
This December, President Trump signed an executive order directing the rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act, a move that carries significant symbolic and economic weight, but also meaningful complexity. While rescheduling alone does not legalize cannabis federally, nor does it instantly rewrite tax code, it materially changes the conversation around Internal Revenue Code Section 280E, which has long prohibited cannabis operators from deducting ordinary business expenses.
If Schedule III status is ultimately codified through formal rulemaking and upheld through implementation, the removal of 280E would represent one of the most impactful economic reforms the industry has ever seen. For operators, this could translate into immediate improvements in after-tax cash flow, expanded reinvestment capacity, and healthier balance sheets, freeing capital that is currently absorbed by punitive tax treatment rather than deployed toward compliance, quality systems, R&D, and workforce development.
That said, the market must remain clear-eyed: executive action is only the first step. Durable change requires regulatory follow-through, IRS guidance, and time. Operators who plan prudently by modeling both outcomes, while strengthening their operational fundamentals, will be best positioned to capture the upside when, and if, the economic burden of 280E is finally lifted.
We’ll be tracking this closely into the new year, and ACT LAB will be sharing a deeper, economics-focused perspective on what rescheduling and potential 280E reform could realistically mean for operators once the regulatory dust settles.
Emphasis on Micro, Metals, and Label Accuracy
In 2026, labs that move fast and think beyond compliance will help shape the future of what’s next in the cannabis industry. Across nearly all markets, regulators are signaling heightened scrutiny of:
Microbial Contaminants
From aspergillus to yeast and mold, microbial safety remains a leading cause of product failures. Changes in climate conditions, facility size, and production volume may increase contamination risk, making proactive environmental monitoring with lab partners essential.
Heavy Metals
As states move toward greater standardization, more jurisdictions are adopting stricter thresholds for arsenic, lead, mercury, and cadmium. Cultivators should expect expanded batch testing and greater accountability for soil and nutrient sourcing.
Potency and Labeling Requirements
Regulators are pushing for greater accuracy in THC, CBD, and minor cannabinoid reporting. Mislabeling fines, required corrective actions, and product recalls have increased nationwide. Cultivators and processors must invest in validated potency testing and tighter QA processes to avoid compliance risks.
The Future of Formulation: What’s Next for Cannabis Products?
As the regulatory environment matures, consumers are becoming more sophisticated and more selective. Product innovation must now blend creativity with scientific rigor. And the brands still relying on trend-driven launches without data-backed validation will soon find themselves outpaced by competitors who treat science as their primary engine of differentiation.
Fast-Acting and Functional Edibles
Operators are increasingly exploring emulsion technologies and rapid-onset formulations to meet demand for products that feel consistent, predictable, and approachable for new consumers. ACT LAB partners with infusion innovators like Azuca, monarQh, SoRSE Technology, and Vertosa with testing methods optimized for these technologies.
Cost-Efficient Potency: The Next Phase of Product Design
As price compression continues across mature cannabis markets, formulation strategies in 2026 are increasingly driven by cost efficiency without sacrificing consumer appeal. Operators are moving away from less efficient inputs like distillate, where higher volumes are required to achieve target potency, and toward more potent formats like liquid diamonds. While liquid diamonds may have a higher price per gram, their superior potency and purity allow for lower input volumes, making them a more cost-efficient choice for product formulations.
All-in-one (AIO) vape formats and infused pre-rolls are also gaining momentum as brands look to combine potency, convenience, and manufacturing efficiency into a single offering. These products allow operators to maximize cannabinoid delivery while streamlining production workflows and reducing per-unit costs. As competition intensifies, the brands that succeed will be those that pair cost-optimized formulations with rigorous testing and validation to ensure potency claims are accurate, products remain compliant, and consumers receive consistent, high-quality experiences.
ACT LAB supports this evolution by helping manufacturers validate new inputs, infusion methods, and high-potency formats with data-driven testing, enabling innovation that is not only competitive, but sustainable.
Infused Beverages
Infused drinks may be positioned for significant growth in 2026, especially in markets where dosage caps or serving limits make beverages a consumer-friendly alternative. However, beverage formulations often require more advanced testing for homogeneity, emulsion stability, and shelf-life performance.
However, we will see volatility in this product category in 2026, with new federal rules sharply restricting total THC content and banning synthetically altered cannabinoids which is expected to upend the infused beverage market. As companies face a one-year transition window, the sector is bracing for widespread reformulation, reduced interstate sales, and a potential shift toward more tightly regulated cannabis-beverage frameworks.
Brands developing and validating new products can’t afford to rely on trial-and-error or outdated assumptions. ACT LAB brings the R&D and regulatory rigor required to ensure quality and compliance, transforming what is typically viewed as a bottleneck into a strategic advantage.
How Cannabis Brands Can Future-Proof Their Operations for 2026
Enhanced Quality Assurance Protocols
Increasing regulatory scrutiny means operators cannot rely solely on compliance-based testing. Forward-thinking cultivators are implementing:
- Routine environmental testing
- In-process checks during cultivation and extraction
- Pathogen risk assessments
- Soil and water monitoring programs
These steps don’t just cut batch failures; they eliminate the hidden operational drag that slows your entire supply chain. By tightening reliability from cultivation through point-of-sale, you keep products moving and prevent the costly disruptions many operators accept as the price of doing business.
R&D Testing for Product Differentiation
Innovative products require iterative refinement. Frequent R&D testing through a third-party testing lab can help validate cannabinoid and terpene profiles, shelf-life stability, and emulsion performance.
Brands that treat their lab as a true formulation partner, not just a compliance checkpoint, are better equipped to innovate responsibly and stay ahead of market trends. Operators investing in R&D are shaping market trends while their competitors scramble to keep up.
Proactive Adaptation to Regulatory Change
Waiting for regulatory changes to officially take effect can be costly, disrupting production timelines, increasing compliance risk, and slowing speed-to-market. Operators can mitigate these risks by evaluating proposed rules early and aligning their processes well before formal implementation. This forward-looking approach ensures operational continuity, protects brand integrity, and preserves market share as the regulatory landscape evolves.
From D9 beverages sold in gas stations to kratom supplements marketed as sleep aids, the lines are blurring, and regulators are watching. ACT LAB is preparing clients for this next wave with precision testing and preventive science by translating upcoming regulatory requirements into actionable testing strategies and operational recommendations, helping operators stay compliant, agile, and ahead of the curve.
Why ACT LAB is the Partner for Your Brand in 2026
With laboratories operating across six states, ACT LAB gives operators something most competitors overlook: a scalable scientific infrastructure built for where the industry is going, not where it’s been.
- Uniform, validated scientific methods across all locations which eliminates inconsistencies that quietly erode product quality
- Market-specific regulatory expertise that anticipates rule changes instead of reacting to them
- Deep technical knowledge spanning cultivation, extraction, and formulation to expose blind spots before they become costly failures
- R&D and pre-compliance testing that accelerate innovation and prevent late-stage reformulations
- Environmental and microbial monitoring designed to reduce facility risk at the source, not after the fact
As the industry moves toward greater standardization, ACT LAB delivers the precision, foresight, and operational confidence that allows leading brands to set the pace while others are forced to follow.
Looking to 2026 and Beyond
As the cannabis industry matures, regulatory expectations will continue to rise in both complexity and consistency. Consumer preferences will keep evolving as new product formats, delivery technologies, and wellness-driven use cases emerge. At the same time, innovation, from genetics and cultivation inputs to advanced extraction and formulation, will only accelerate to reshape what it means to compete in this market.
Cultivators and processors who prioritize scientific rigor, invest in proactive compliance planning, and partner with trusted, data-driven laboratories will be best positioned to thrive. These operators will not only meet regulatory requirements, they’ll anticipate them by understanding their products at a deeper level, iterating faster, and building the kind of quality-driven reputation that sustains long-term growth.
At ACT LAB, we’re not just following the trends, we’re shaping them. With expansion into testing wellness products like kratom and the development of new methods aligned with industry leaders in infusion, terpene, and decontamination technologies, we’re ensuring science leads the way. Through comprehensive testing, regulatory guidance, and forward-looking R&D support, we help operators move faster, comply smarter, and differentiate with confidence in 2026, and well beyond.
To learn more about ACT LAB’s commitment to elevating cannabis innovation for the years ahead, connect with our team.
